Morgan Stanley Maintains Overweight on Alumis, Raises Price Target to $38
3/20/2026
Impact: 75
Healthcare
Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Alumis (NASDAQ: ALMS) and increased the price target from $33 to $38. This adjustment reflects a positive outlook for the company's performance.
AI summary, not financial advice
Share: